Literature DB >> 30431666

Venetoclax plus decitabine induced complete remission with molecular response in acute myeloid leukemia relapsed after hematopoietic stem cell transplantation.

Giacomo Andreani1, Matteo Dragani1, Anna Serra1, Paolo Nicoli1, Marco De Gobbi1, Daniela Cilloni1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30431666     DOI: 10.1002/ajh.25352

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  3 in total

Review 1.  Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Are Supporting Evidences Enough?

Authors:  Serena Brancati; Lucia Gozzo; Giovanni Luca Romano; Calogero Vetro; Ilaria Dulcamare; Cinzia Maugeri; Marina Parisi; Laura Longo; Daniela Cristina Vitale; Francesco Di Raimondo; Filippo Drago
Journal:  Cancers (Basel)       Date:  2021-12-21       Impact factor: 6.639

2.  Venetoclax plus azacitidine and donor lymphocyte infusion in treating acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation.

Authors:  Peng Zhao; Ming Ni; Dan Ma; Qin Fang; Yan Zhang; Yanju Li; Yi Huang; Ying Chen; Xiao Chai; Yun Zhan; Yan Li; Qian Kang; Mei Zhao; Min Liu; Fengqi Zhang; Shisi Huang; Shuangshuang Wen; Bo Deng; Jishi Wang
Journal:  Ann Hematol       Date:  2021-09-27       Impact factor: 3.673

3.  Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.

Authors:  Esther Schuler; Eva-Maria Wagner-Drouet; Salem Ajib; Gesine Bug; Martina Crysandt; Sabine Dressler; Andreas Hausmann; Daniela Heidenreich; Klaus Hirschbühl; Matthias Hoepting; Edgar Jost; Jennifer Kaivers; Stefan Klein; Michael Koldehoff; Lambros Kordelas; Oliver Kriege; Lutz P Müller; Christina Rautenberg; Judith Schaffrath; Christoph Schmid; Daniel Wolff; Rainer Haas; Martin Bornhäuser; Thomas Schroeder; Guido Kobbe
Journal:  Ann Hematol       Date:  2020-11-16       Impact factor: 3.673

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.